Older, archived, paediatric news
These links are provided for information only. NPPG is not responsible for the content of any link
June 2021
- European CHMP recommends paediatric license extension of migalastat (Galafold)
- European CHMP recommends license extension of tofacitinib (Xeljanz) for treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis
- European CHMP recommends approval of vosoritide (Voxzogo) for treatment of achondroplasia in patients aged 2 years
- Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial
- Clinical Commissioning Urgent Policy Statement: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease
- FDA accepts resubmission of New Drug Application for unique formulation of sodium thiosulfate, Pedmark for prevention of cisplatin-induced ototoxicity in children with localised, non-metastatic solid tumours
- Court of Appeal considering whether under-16s can give informed consent to medical treatment that delays onset of puberty.
- New product: Ascorbic Acid Pascoe 150 mg/ml Concentrate for solution for injection / infusion
- FDA approves dabigatran etexilate oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism
- European Commission grants conditional approval selumetinib (Koselugo) for treatment of children with symptomatic, inoperable plexiform neurofibromas (PN) and neurofibromatosis type 1 (NF1)
- European approval of paediatric license extension of teriflunomide (Aubagio) for treatment of relapsing remitting multiple sclerosis in patients aged 10 to 17 years
- Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
- Enhanced service specification: Long COVID 2021/22
- Treatment of Multisystem Inflammatory Syndrome in Children
- Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
- Implementing a specialist Paediatric Clinical Pharmacology Service in a UK Children’s Hospital
- Levetiracetam in Lactation: How Much is Excreted into the Human Breast Milk?
- Should we vaccinate children against SARS-CoV-2?
- NHS is to set up specialist long COVID services for children and young people as part of a £100 million expansion of care
- Role of C reactive protein and procalcitonin in the diagnosis of lower respiratory tract infection in children in the outpatient setting
- Letter to women and girls taking sodium valproate
- Updated Publication of Remdesivir guidance for patients hospitalised with Covid-19 (adults and children aged 12 years and older)(version 3; updated 14/6/21)
- Genetech announce new interim data from two studies (JEWELFISH and RAINBOWFISH) of risdiplam (Evrysdi) in spinal muscular atrophy (SMA)
- FDA grant approval for new paediatric indication for Lymphoseek (technetium Tc 99m tilmanocept) injection
- FDA approve expansion of the paediatric indication of sofosbuvir/velparasvir (Epclusa) for the treatment of chronic hepatitis C virus to include children from the age of 3 years and above
- Company announces new data analysis from multiple Phase 2 and 3 studies of the long-term efficacy of nusinersen (Spinraza) therapy in spinal muscular atrophy (SMA)
- American College of Rheumatology Guidance for the management of pediatric rheumatic disease during the covid-19 pandemic: Version 2
- Vigabatrin (Kigabeq) accepted for restricted use within NHS Scotland for treatment of infantile spasms and resistant partial epilepsy
- FDA approve secukinumab for treatment of children and adolescents with moderate to severe plaque psoriasis
- European Medicines Agency’s CHMP recommends granting of extension of indication for Pfizer and BioNTech COVID-19 vaccine (Comirnaty) to include use in children aged 12 to 15 in EU
- A guide to immunisations for babies born on or after 1 January 2020
May 2021
- Shortage of Alliance Calcium Syrup SPS memo discussing alternatives
- Epilepsy in children – patient information booklets
- Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study
- Manufacturers report positive results for dupilumab in childhood asthma
- Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
- α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder
- Management of chronic asthma in children aged 16 years and under – Report
- Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
- Vaccinating children against SARS-CoV-2
- Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children
- FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 vaccine to include adolescents age 12 to 15 years of age
- MHRA approves licence extension for cystic fibrosis (CF) treatment Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor
- The effect of diet in infancy on asthma in young adults: the Merthyr Allergy Prevention Study
- EMA starts evaluating use of Comirnaty, COVID-19 vaccine, in young people aged 12 to 15
- Paediatric expansion for Phase 3 PREVENT-19 trial of COVID-19 vaccine NVX-XoV2372
- Paediatric pharmacotherapy and drug regulation: Moving past the therapeutic orphan
- Revised SPC: Minims Phenylephrine Hydrochloride 10%w/v Eye drops, solution
April 2021
- Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes
- Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency
- Zolgensma®▼ (onasemnogene abeparvovec): Risk for thrombotic microangiopathy
- Revised SPC: Sporanox (itraconazole) oral suspension use in cystic fibrosis
- European CHMP recommends paediatric license extension of teriflunomide (Aubagio) for treatment of relapsing remitting multiple sclerosis
- European CHMP recommends paediatric license extension of glecaprevir / pibrentasvir (Maviret) for treatment of chronic hepatitis C infection
- European CHMP recommends approval of selumetinib (Koselugo) for treatment of paediatric neurofibromatosis type 1 plexiform neurofibromas
- Positive results of Phase III study of adapalene/benzoyl peroxide/clindamycin gel (IDP-126) in acne vulgaris announced
- April BNF/BNF for Children newsletter
- Compassionate Use of Remdesivir in Children With Severe COVID-19
- Cannabidiol (Epidyolex) approved in the EU for the treatment of seizures associated with tuberous sclerosis complex
- Post-natal care – guidance (NG194)
- Neonatal infection – antibiotics for prevention and treatment NICE Guideline NG195
- NHS England to set up independent review group to assess prescription of puberty blockers for children under 16
- US FDA grants pamrevlumab Rare Pediatric Disease Designation for the treatment of Duchenne Muscular Dystrophy
- Continued improvements in motor milestones reported in infants with Type 1 Spinal Muscular Atrophy after two years of treatment with risdiplam
- FDA grant Orphan Drug and Rare Paediatric Disease Designations for AK-OTOF for the treatment of otoferlin gene-mediated hearing loss
- Clinical Commissioning Policy: Sodium oxybate for symptom control of narcolepsy with cataplexy (children and adolescents aged 7 until 19 years)
- SARS-CoV-2–Specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women
- Paediatric contraindication for chloramphenicol eye drops
- Revised SPC: Keytruda (pembrolizumab) 25 mg/mL concentrate for solution for infusion
- Using bolus injections in neonates, children and young people
- Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial
- Preliminary data suggest 100% vaccine efficacy with Pfizer-BioNTech COVID-19 vaccine in children aged 12 to 15
- US FDA approves viloxazine extended-release capsules for treatment of attention-deficit hyperactivity disorder (ADHD) in paediatric patients 6-17 years of age
- New product: Vaxelis suspension for injection in pre-filled syringe
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation
- Free app reduces kids ‘basic advice’ visits to A&E
- Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma
- Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria
March 2021
- Risdiplam approved for use in EU for the treatment of spinal muscular atrophy
- FDA approve of Vyxeos (daunorubicin and cytarabine) for the secondary Acute Myeloid Leukemia in paediatric patients
- European CHMP recommends license extension of ivacaftor / tezacaftor / elexacaftor (Kaftrio) and ivacaftor (Kalydeco) for cystic fibrosis
- European CHMP recommends approval of modified-release hydrocortisone (Efmody) for treatment of congenital adrenal hyperplasia for patients aged 12 years and older
- Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
- Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials
- The best start for life: a vision for the 1,001 critical days
- Zegalogue (dasiglucagon) approved for severe hypoglycaemia in people with diabetes in the US
- BMJ collection: Child health redesign
- Cystic fibrosis mRNA candidate (MRT5005) fails to show benefit in Phase I/II clinical trial
- European Commission approves licence extension for pembrolizumab as monotherapy for treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL)
- Melatonin (Slenyto®) recommended as option for use within NHS Wales
- Dupilumab (Dupixent®) recommended for restricted use within NHS Wales in children age 6 to 11 years
- NICE issues draft guidance on babies, children and young people’s experience of healthcare
- FDA approves once-daily Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) capsules for treatment of ADHD symptoms in patients aged 6 years and older
- FDA accepts for review supplemental Biologics Licence Application (sBLA) for dupilumab in treatment of children aged 6 to 11 years with uncontrolled moderate-to-severe asthma
- Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndrome
- Mycosis Fungoides in Children and Adolescents: A Systematic Review
- Indomethacin for symptomatic patent ductus arteriosus in preterm infants
- Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET
- Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
- European CHMP recommends approval of risdiplam (Evrysdi) for treatment of spinal muscular atrophy
- Acute covid-19 and multisystem inflammatory syndrome in children
- Rapid lateral flow testing for households and bubbles of school pupils and staff
February 2021
- Data from pooled safety analysis in patients treated with Palforzia (peanut allergen powder) presented at conference
- Revised SPC: Episenta (sodium valproate) 500 mg prolonged-release granules
- Briefing: Can variation help to explain the rise in emergency admissions for children aged under five up to 2018/19?
- Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bone health
- Magnesium sulphate for treating acute bronchiolitis in children up to two years of age
- Atopic dermatitis in children: when topical steroid treatment “does not work”
- Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
- Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth
- Alkindi (hydrocortisone granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules
- Medicines in pregnancy and breastfeeding: new initiative for consistent guidance; report on optimising data for medicines used during pregnancy
- Risk minimisation materials: Pro-Epanutin (fosphenytoin)
- Revised SPC: Tivicay (dolutegravir) 5 mg dispersible tablets
- Large UK study finds children with COVID-19 less likely to report fever, persistent cough or appetite loss
- Botox® (onabotulinumtoxinA) receives US FDA approval for paediatric Detrusor Overactivity associated with a neurologic condition
- Efficacy and safety of tocilizumab for polyarticular‐course juvenile idiopathic arthritis in the open‐label two‐year extension of a phase III trial
- Transforming the care of children and young people (CYP) in London with asthma: Development of the London Asthma Standards
- Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
- European CHMP recommends approval of salmeterol / fluticasone (BroPair Spiromax and Seffalair Spiromax) for treatment of asthma
- European CHMP recommends approval of paediatric license extension for pembrolizumab (Keytruda)
- European CHMP recommends approval of paediatric license extension for bedaquiline (Sirturo)
January 2021
- Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
- The state of children’s mental health services 2020/21
- January BNF/BNF for Children newsletter
- Preservation of fertility in teenagers and young adults treated for haematological malignancies
- Healthcare Safety Investigation Branch (HSIB) launches investigation into weight-based medication errors in children
- Factors influencing the implementation of clinical pharmacy services on paediatric patient care in hospital settings
- Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis
- PRAC concludes evaluation of risk of acute adrenal insufficiency in children when switching to Alkindi (hydrocortisone) granules
- Dispersible tablet formulation of dolutegravir (Tivicay) in paediatric patients aged at least four weeks and weighing at least 3kg approved in EU
- Valproate use by women and girls
- Use of medicines in pregnancy and breastfeeding
- Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
- Guidance on the hepatitis B antenatal screening and selective neonatal immunisation pathway
- FDA accepts for Priority Review New Drug Application for mirabegron oral suspension and supplemental New Drug Application for Myrbetriq (mirabegron) tablets in paediatric patients with neurogenic detrusor overactivity (NDO)
- Safety of COVID-19 vaccines when given in pregnancy
- Revised SPC: Xyrem (sodium oxybate) 500 mg/ml oral solution
- Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children
- DTB select: Can emollient use in early infancy prevent eczema?
- Safety of clonidine used for long‐term sedation in paediatric intensive care: A systematic review
- Revised SPC: Dupixent 200 mg solution for injection in pre-filled pen and syringe
- Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis
December 2020
- European approval of Palforzia for desensitising children and adolescents to peanut allergy
- No population left behind: improving paediatric drug safety using informatics and systems biology
- Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- New product: Desizon (zonisamide) 20 mg/ml oral suspension
- Neonatal infection: antibiotics for prevention and treatment
- Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants
- Establishing dose‐bands for commonly prescribed oral medications for children in the UK: Results of a Delphi study
- NIHR Alert: Rituximab helps cure almost all children with non-Hodgkin’s lymphoma
- Why breastfeeding is important and how pharmacy can help
- Advising on medicines regimens during breastfeeding
- Pneumococcal conjugate vaccines for preventing acute otitis media in children
November 2020
- New product: Revolade (eltrombopag olamine) oral suspension
- European approval of paediatric license extension of dupilumab (Dupixent) for severe atopic dermatitis
- Revised SPCs: Kalydeco (ivacaftor) granules in sachet – all strengths includes patients aged at least 4 months and weighing >5kg
- Acute otitis media in children
- NIHR Alert: Teenagers’ use of antidepressants is rising with variations across regions and ethnic groups
- European CHMP recommends paediatric license extension and paediatric formulations of dabigatran etexilate (Pradaxa)
- European CHMP recommends paediatric license extension and new strength of rivaroxaban (Xarelto)
- European CHMP recommends paediatric license extension and new formulation of dolutegravir (Tivicay)
- European CHMP recommends license extension sodium oxybate (Xyrem)
- What injections can be given orally or via enteral feeding tubes?
- Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
- Alternative parenteral acid suppressants covering main indications of intravenous ranitidine in children
- Sapropterin for phenylketonuria (all ages)
- Mercaptamine hydrochloride viscous eyedrops for corneal cystine deposits in people aged older than 2 years
- Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass
October 2020
- Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey
- Observational study of drug-related problems and clinical pharmacists’ interventions in a French paediatric hospital
- Association of Maternal Prepregnancy Diabetes and Gestational Diabetes Mellitus With Congenital Anomalies of the Newborn
- Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants
- Manufacturers report positive results for dupilumab in Phase III paediatric asthma study
- Is it safe to use visible blue light-emitting diode phototherapy for neonatal jaundice in infants who are also treated with amiodarone?
- Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis
- Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT))
- Positive Phase III data for somatrogon in children (3 to <18 years) with growth hormone deficiency
- FDA grants givinostat Rare Paediatric Disease Designation for Duchenne Muscular Dystrophy
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults
- Corticosteroid therapy for nephrotic syndrome in children
- Giving oral medicines and supplements to children
- Neonatal sepsis
- FDA approves licence extension of golimumab to include paediatric use for active psoriatic arthritis
- Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial
- Beta‐blockers for congestive heart failure in children
September 2020
- Advances in understanding and reducing the burden of severe asthma in children
- Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
- Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial
- US FDA approves Xeljanz (tofacitinib) tablets and oral solution for the treatment of active polyarticular course juvenile idiopathic arthritis
- US FDA approves Haegarda – a subcutaneous C1 esterase inhibitor for prevention of hereditary angioedema (HAE) attacks in paediatric patients
- FDA grants setrusumab rare pediatric disease designation for treatment of osteogenesis imperfecta (OI)
- FDA assigns orphan drug and rare pediatric disease designations to SPIRO-2101 for treatment of cystic fibrosis
- Growth concerns in the early weeks of life
- FDA accepts supplemental new drug application for crizotinib for treatment of paediatric ALK-positive anaplastic large cell lymphoma
- Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study
- Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children
- Levetiracetam add‐on for drug‐resistant focal epilepsy
- Inhaled mannitol for cystic fibrosis
- Early versus late parenteral nutrition for critically ill term and late preterm infants
- Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children
- Cannabidiol (Epidyolex®) accepted for use within NHS Scotland for Lennox-Gastaut syndrome
- Cannabidiol (Epidyolex®) accepted for use within NHS Scotland for Dravet syndrome
- Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children
- Vaccines for measles, mumps, rubella, and varicella in children
- Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents
- Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long‐term central venous catheters in infants and children
- FDA to review licence extension for elexacaftor/tezacaftor/ivacaftor and ivacaftor for additional CFTR mutations
- Psychiatric drugs given to children and adolescents have been ranked in order of safety
-
Paediatric data for elexacaftor/tezacaftor/ivacaftor in the treatment of cystic fibrosis (CF)
- Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children
- Vaccines for measles, mumps, rubella, and varicella in children
- Clonazepam add‐on therapy for drug‐resistant epilepsy
August 2020
- FDA approves automated insulin delivery and monitoring system for use in children aged 2 to 6 with type 1 diabetes
- Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
- Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
- Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study
- Introduction of a prescribing ward round to reduce prescribing errors on a paediatric intensive care unit
- Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
- Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial
- Improving pain management in childhood acute otitis media in general practice: a cluster randomised controlled trial of a GP-targeted educational intervention
- Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants
- Surfactant for pulmonary haemorrhage in neonates
- EU grants marketing authorisation of ivacaftor/tezacaftor/elexacaftor (Kaftrio) for cystic fibrosis
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
- NICE consults on draft quality standard on fetal alcohol spectrum disorder
- Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
- Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization
- Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women
- Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
- Air pollution and family related determinants of asthma onset and persistent wheezing in children: nationwide case-control study
- COVID-19 and multisystem inflammatory syndrome in children and adolescents
- Early Access to Medicines Scheme (EAMS) positive scientific opinion: Dupilumab in the treatment of children aged 6 to 11 years of age with severe atopic dermatitis (allergic eczema)
- New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.
- Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
- Anti‐inflammatory medications for obstructive sleep apnoea in children
- Paracetamol (acetaminophen) for prevention or treatment of pain in newborns
- Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
- Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
- Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
- Intravenous immunoglobulin for suspected or proven infection in neonatesCochrane update of review 9 studies, n=3,973)
- Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infantsCochrane review 9 studies (n=5,000)
- FDA approves risdiplam for spinal muscular atrophy in adults and children
- Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects
- Corticosteroids for treating sepsis in children and adults
- Protecting your child against flu: Information for parents and carers
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
- New product: Treprostinil Tillomed 5 mg/ml and 10 mg/ml solution for infusion
July 2020
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children
- Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study
- Statins for children with familial hypercholesterolemia
- Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study
- Medical and surgical interventions for the treatment of urinary stones in children
- Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
- Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy
- New Product: Hydrocortisone 10mg soluble tablets (Creo Pharma)
- Positive phase III data from post-marketing study of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people ages 12 and older with cystic fibrosis who have one copy of F508del mutation and one gating or residual function mutation
- Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany
- Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer
- Specialist neonatal respiratory care for babies born preterm- quality standard (QS193)
- Methylphenidate and mortality in children with attention-deficit hyperactivity
- Clinical Commissioning Policy: Vedolizumab for refractory ulcerative colitis in pre-pubescent children
- The routine immunisation schedule from June 2020
- European Medicines Agency to host workshop on safe use of medicines during pregnancy and breastfeeding
- U.S. FDA grants Rare Paediatric Disease Designation to silmitasertib for treatment of recurrent sonic hedgehog medulloblastoma
- U.S. FDA grants Orphan Drug Designation to gene therapy for treatment of CLN5 Batten Disease
- Patients with cystic fibrosis to have access to Kaftrio (ivacaftor/tezacaftor/elexacaftor) under deal between NHS and Vertex
- New product: Zolgensma (onasemnogene abeparvovec) 2 x 1013 vector genomes/mL solution for infusion
June 2020
- Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
- Multisystem Inflammatory Syndrome in Children in New York State
- European CHMP recommends approval of caffeine citrate (Gencebok) for treatment of primary apnoea of premature newborns
- Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic
- Childhood Trust report warns of serious mental health conditions in children due to COVID-19
- Gilead announces plans to study remdesivir in paediatric patients with COVID-19
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis
- FDA grants approval of dispersible tablet formulation of dolutegravir and extension of paediatric indication for HIV
- COVID-19 – ‘shielding’ guidance for children and young people updated
- Two-year results from ARC004, a follow-on study to phase 3 PALISADE trial of Palforzia (peanut allergen powder) in patients with peanut allergy
- Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis
- Intravenous fluid therapy in children and young people in hospital- updated guidance (NG29)
- Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
- COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
- Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
- Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
May 2020
- Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic
- Hyperinflammatory shock in children during COVID-19 pandemic
- DTB select: Dexamethasone or prednisolone for croup
- COVID-19 Guidance – Paediatric multisystem inflammatory syndrome temporally associated with COVID-19
- European CHMP recommends approval of wider use of ivacaftor in patients with cystic fibrosis and an R117H mutation in the CFTR gene
- European CHMP recommends approval of Harvoni (ledipasvir and sofosbuvir) for the treatment of paediatric patients with chronic hepatitis C
- COVID-19 rapid guideline: children and young people who are immunocompromised – guidance (NG174)
April 2020
- April BNF/BNFc Newsletter
- Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort
- Mental Health Status Among Children in Home Confinement During the Coronavirus Disease 2019 Outbreak in Hubei Province, China
- JCVI statement on immunisation prioritisation
- Can breastfeeding mothers take paracetamol or paracetamol combination products?
- Revised SPC: Revatio (sildenafil) preparations – risks outweigh benefits in PPH in newborn
- FDA approves selumetinib (Koselugo) for the treatment of children aged from 2 years with neurofibromatosis type 1
- NHS England Speciality Guide: Urgent and emergency musculoskeletal conditions in children (under 16) requiring onward referral
- Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group
- COVID-19 rapid guideline: cystic fibrosis- guideline (NG170)
- COVID-19 rapid guideline: severe asthma – guidance (NG166)
- National Patient Safety Alert: Interruption of high flow nasal oxygen during transfer
March 2020
- Paediatric to adult transition care for patients with sickle cell disease: a global perspective
- COVID-19: guidance on supporting children and young people’s mental health and wellbeing
- COVID-19 infection in children
- CHMP recommends licence extension for etravirine (Intelence)
- CHMP recommends licence extension for conestat alfa (Ruconest)
- US FDA accepts New Drug Application (NDA) for new formulation of baloxavir for the treatment of influenza in children
- Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
- Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn
- Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies
- Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study
- SARS-CoV-2 Infection in Children
- February BNF/BNFC newsletter
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- Clinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages)
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Clinical Commissioning Policy: Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)
- Revised SPC: Dioralyte products
- New product: Adynovi (rurioctocog alfa pegol) 1000 IU powder and solvent for solution for injection 2 ml solvent
- Cardiovascular Health Trajectories From Childhood Through Middle Age and Their Association With Subclinical Atherosclerosis
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Bronchiolitis: when less is more
- Import restrictions changed for cannabis-based medicines to allow faster access
- Ensuring access to safe, effective, and affordable cannabis‐based medicines
- State of Child Health in the UK
- FDA Grants rare paediatric disease designation for elamipretide for Barth Syndrome
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis A Systematic Review and Network Meta-analysis
- Canakinumab for Periodic Fever Syndromes in children to be commissioned by NHS England
February 2020
- Neonatal parenteral nutrition – guidance [NG154]
- Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study
- Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
- Plerixafor (Mozobil®) recommended for use within NHS Wales in combination with G-CSF
- New advances in the treatment of paediatric functional abdominal pain disorders
- Asthma: diagnosis, monitoring and chronic asthma management- updated guideline (NG80)
- Young people’s mental health and wellbeing research
- Refractory Epilepsy Specialist Clinical Advisory Service
- Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction
- A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents
- Lower versus Traditional Treatment Threshold for Neonatal Hypoglycemia
- US FDA approves Palforzia (Arachis hypogaea) Allergen Powder capsules for treatment of peanut allergy
January 2020
- Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of rituximab (MabThera) for paediatric patients
- Update on gender identity development service for children and young people
- First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations
- Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- US FDA approved fidaxomicin oral suspension for clostridioides difficile-associated diarrhoea (CDAD) in children aged six months and older
- Assessing coverage of interventions for reproductive, maternal, newborn, child, and adolescent health and nutrition
- European Medicines Agency approves license extension for ustekinumab to include treatment of plaque psoriasis in children between 6 and 11 years
- Duchenne muscular dystrophy (DMD)
- Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
- January BNF/BNFC Newsletter
- Where next for inhaled corticosteroids in childhood asthma?
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- Sodium valproate Pregnancy Prevention Programme – updated Guide for Healthcare Professionals
- A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
- Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort
- Precocious puberty
- Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy
- Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial
- Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy
- Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen
December 2019
- In use product safety assessment report for Alkindi (hydrocortisone) granules in capsules for opening
- Paediatric Intensive Care Audit Network: Annual Report 2019
- NICE Bites – Fever in under 5s
- European Paediatric Formulary of extemporaneous preparations goes live
- December BNF/BNFC Newsletter.
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
- Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome – guidance (TA615)
- Cannabidiol with clobazam for treating seizures associated with Dravet syndrome – guidance (TA614)
- Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- Approval of licence extension for cystic fibrosis therapy ivacaftor (Kalydeco)
- Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
- Association Between Fertility Treatment and Cancer Risk in Children
- Summary of American Academy of Neurology guideline for acute treatment of migraine in children and adolescents and pharmacologic treatment for paediatric migraine prevention
- Does general anaesthesia affect neurodevelopment in infants and children?
- Revised SPC: Diovan 3 mg/ml Oral Solution (valsartan) – licensed for ages 1 to 6
- Clinical Commissioning Policy: Maternal intravenous immunoglobulin (IVIg) for the prevention of allo-immune fetal and neonatal haemochromatosis
- HPV: WHO calls for countries to suspend vaccination of boys
- National measles guidelines
November 2019
- General Pharmaceutical Council launches new guidance for pharmacist prescribers to ensure safe and effective prescribing
- Supply Disruption Alert: Emerade 150 microgram, 300 microgram and 500 microgram adrenaline auto-injector devices
- FDA approves Toujeo (insulin glargine) to treat childhood type 1 diabetes
- Educational Risk Minimisation Materials to help reduce the risk associated with using glycopyrronium bromide (Sialanar) 320 micrograms /ml Oral Solution
- November BNF/BNFC Newsletter
- Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study
- Pre-school vaccinations: guide to vaccinations from 2 to 5 years
- Revised SPC: Qvar (beclometasone dipropionate) MDI – all strengths – pescribing information for 5 years and above
- Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study
- Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations
- School-based interventions to prevent anxiety and depression in children and young people: a systematic review and network meta-analysis
- Practical aspects of childhood epilepsy
- Flu-vaccine nasal spray delayed for some schoolchildren
- Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome – Final Appraisal Determination
- Urgent Policy Statement: Cystic Fibrosis Modulator Therapies
- Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
- Sanofi presents data from EDITION JUNIOR phase III trial of Toujeo (insulin glargine 300 Units/mL) vs. insulin glargine 100 Units/mL (Gla-100) in children and adolescents aged 6 to 17 years with type 1 diabetes
- NIHR Signals: Antimicrobial central venous catheters do not reduce infections in pre-term babies
- Fever in under 5s: assessment and initial management- guidance (NG143)
- Paediatric critical care and surgery in children review: Summary report
- Human and animal bites: antimicrobial prescribing – Draft guidance consultation
- Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial
- Immunisations: babies up to 13 months of age
- FDA statement on new testing results, including low levels of impurities in ranitidine drugs
- Narsoplimab receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan required for licensing application
- Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood
- Zanamivir (Dectova®)
- Belimumab licence extension for use in children from age 5 approved in the European Union
- BNF/BNFC newsletter October 2019
October 2019
- Investigation into pre-school vaccinations routinely provided in England in 2018/2019
- FDA approves license extension for Botulinum A toxin for treatment of lower limb spasticity in children and adolescents aged 2 to 17 years
- Perinatal Management of Extreme Preterm Birth before 27 weeks of gestation: A Framework for Practice
- Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial
- Incidence of anorexia nervosa in young people in the UK and Ireland: a national surveillance study
- Committee for Medicinal Products for Human Use (CHMP) recommends approval of Baqsimi (glucagon)
- Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort
- Letter to healthcare professionals regarding parenteral nutrition products for neonates and children below 2 years of age – protect from light
- Adrenaline auto-injectors: recent actions taken to support safety
- Differences in lung function between children with sickle cell anaemia from West Africa and Europe
- Duration of intravenous antibiotic therapy in people with cystic fibrosis
- NICE draft Quality Standard published for consultation: Specialist neonatal respiratory care for babies born preterm
- Band ligation versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
- Mandatory childhood vaccination could cause “irreparable damage,” says expert panel
- Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
- Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
- Gastro-oesophageal reflux disease in children and young people: diagnosis and management – updated guidance (NG1)
- Fetal Alcohol Spectrum Disorder (FASD)
- New product: Epidyolex (cannabidiol) 100 mg/ml oral solution
- FDA accepts for review two New Drug Applications (NDAs) for fidaxomicin to treat children aged six months up to 18 years with Clostridium difficile infections
- Epilepsies: diagnosis and management- updated clinical guideline (CG137)
September 2019
- September 2019 BNF/BNFc newsletter
- US FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids
- Pfizer announces positive results for abrocitinib in atopic dermatitis for patients 12 and older
- Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions
- Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for treatment of upper limb spasticity in children, excluding cerebral palsy
- DTB Commentary: Do oral steroids improve hearing outcomes in children with otitis media with effusion?
- TNF‐α blockers for the treatment of Kawasaki disease in children
- Childhood Vaccination Coverage Statistics – England 2018-19
- Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
- European CHMP issues positive opinion for paediatric license extension of belimumab (Benlysta)
- Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
- Pneumonia (hospital-acquired): antimicrobial prescribing- guideline [NG139]
- Sulthiame add‐on therapy for epilepsy
- Attention deficit hyperactivity disorder: diagnosis and management – updated guidance (NG87)
- UK immunisation schedule: the green book, chapter 11 updated
- FDA approves hydroxyprogesterone caproate (HPC) to prevent preterm birth
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
- Methylphenidate and stuttering
- Neonatal parenteral nutrition – draft guidance
- Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017
- Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study
- Twin and triplet pregnancy – guidance (NG137)
- NHS warning to parents as ‘asthma season’ hits
- August BNF/BNFC eNewsletter
- Vancomycin is commonly under‐dosed in critically ill children and neonates
- Revised SPCs: Strensiq (asfotase alfa) solution for injection (all strengths)
August 2019
- WHO revision of pain management guidelines
- Four European nations lose measles eradication status
- HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
- MMR vaccine for 10 to 11 year old children: information for GPs
- Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome – Appraisal Consultation document
- Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome – appraisal consultation document
- European Commission grants extension of indication for Fiasp (insulin aspart) for use in children
- Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)
- Estimated 1 in 7 five years olds are not immunised against MMR
- NHS England to look at offering childhood vaccinations in healthcare settings other than general practice to increase childhood vaccine coverage
- Revised SPC: Dupixent (dupilumab) 300 mg solution for injection in pre-filled syringe – new paediatric indication
- Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial
- Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis
- Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk
- Antibiotic exposure and ‘response failure’ for subsequent respiratory tract infections: an observational cohort study of UK preschool children in primary care
- Inhaled corticosteroids for cystic fibrosis
- Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children
- New products: Amglidia (glibenclamide) 0.6 mg/mL and 6 mg/mL, oral suspension
- How and why porcine gelatine is used in vaccines for immunisation programmes
- A quick reference guide to Flu vaccines for children for winter 2019 to 2020
- Long-term risk of infections after treatment of childhood leukemia: a population-based cohort study using administrative health data
- Interventions for preventing obesity in children
- What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
- Manufacturers report positive results for dupilumab for severe atopic dermatitis in children aged 6-11 years
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
- Respiratory syncytial virus (RSV): a scourge from infancy to old age
- Unmasking the vulnerabilities of uninfected children exposed to HIV
- Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
- Probiotics for preventing acute otitis media in children
- Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I
- Educational Risk Minimisation Materials to help reduce the risk associated with the use of glycopyrronium bromide 1 mg/5 ml oral solution
- Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
- Preterm labour and birth – updated guideline (NG25)
- Lipid emulsions for parenterally fed term and late preterm infants
- Lipid emulsions for parenterally fed preterm infants
July 2019
- European CHMP issues positive opinion recommending approval of license extension for Lucentis (ranibizumab) for treatment of ROP in preterm infants
- British guideline on the management of asthma- update
- Nusinersen for treating spinal muscular atrophy-technology appraisal guidance (TA588)
- Young people among those set to benefit from “hole in the heart” closure as part of the NHS Long Term Plan
- Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study
- Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events
- NIHR Signal: Levetiracetam is a useful alternative to phenytoin in stopping prolonged epileptic seizures in children
- NIHR Signal Insights into the transfer between children’s and adults’ services for young people with selected long-term conditions
- Autumn 2019: Complete Routine Immunisation Schedule
- Revised SPCs: Numeta E emulsion for infusion (all strengths).
- Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study
- From September 2019, boys in school year 8 to be offered the free Human Papilloma Virus (HPV) vaccine
- Conference report: positive results reported for rivaroxaban in paediatric venous thromboembolism
- Vitamin D for secondary prevention of acute wheeze attacks in preschool and school-age children
- Nusinersen (Spinraza) access agreement extended for paediatric spinal muscular atrophy
- Behind the Headlines: Asthma attacks triple when children return to school in September
- Suspected neurological conditions: recognition and referral – guidance (NG127)
- Intravenous sildenafil fails to provide benefit for treatment of neonates with persistent pulmonary hypertension (PPHN)
- Pediatric Post–Cardiac Arrest Care: A Scientific Statement From the American Heart Association
- Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association
- Phase 4 CrisADe CARE 1 study evaluating crisaborole ointment 2% in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis meets primary safety endpoints
- Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 Multicenter, Randomized Phase III Trial
- Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
- Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates
June 2019
- Tackling childhood obesity: £1.5 million funding for local projects
- Depression in children and young people: identification and management – guidance (NG134)
- Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
- NIHR Signal: antimicrobial central venous catheters (CVCs) do not reduce infections in pre-term babies
- Pneumococcal conjugate vaccines for preventing acute otitis media in children
- Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes
- US FDA approves liraglutide (Victoza) for type 2 diabetes in children aged over 10 years
- The evolving research agenda for paediatric tuberculosis (TB) infection
- NHS England seeks feedback from commissioners on childhood obesity strategy
- Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study
- Updated guidelines on post-exposure prophylaxis for measles issued
- US FDA grants priority review to rituximab in combination with glucocorticoids for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children from age two years
- The association between maternal body mass index and child obesity: A systematic review and meta-analysis
- Adjusting the dose in paediatric care: dispersing four different aspirin tablets and taking a proportion
- fluticasone propionate/formoterol fumarate (Flutiform®) accepted for use within NHSScotland in children aged 5-12 years
- fingolimod (Gilenya®) accepted for use within NHSScotland in children aged 10-18 years
- Increasing influenza immunisation uptake among children – leaflet for general practice
- Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
- Childhood Asthma Management in Primary Care – Implementation of Exhaled Nitric Oxide and Spirometry Testing (CHAMPIONS study)
- Should measles vaccination be compulsory?
- Pivotal phase III ARTEMIS trial reports consistent safety and efficacy of AR101 in children and adolescents with peanut allergy
- Rotavirus vaccine (Rotarix®): patient group direction (PGD) template (updated)
- MenACWY vaccine (Menveo® or Nimenrix®): patient group direction (PGD) template (updated)
- Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study
- Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder
- Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events
- Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT
May 2019
- May BNF/BNFC eNewsletter
- Prevalence of maternal mental illness among children and adolescents in the UK between 2005 and 2017: a national retrospective cohort analysis
- US FDA approves gene therapy onasemnogene abeparvovec-xioi to treat paediatric patients (less than 2 years of age) with spinal muscular atrophy (SMA)
- Maternal and fetal outcomes in pregnancies complicated by Marfan syndrome
- Interventions to improve the mental health of children and young people with long-term physical conditions: linked evidence syntheses
- Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials
- Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study
- Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014
- Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery
- Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps
- US FDA approves nasal midazolam for acute repetitive seizures
- Fragmin (dalteparin sodium) approved by FDA as first anticoagulant for children
- Hepatic late adverse effects after antineoplastic treatment for childhood cancer
- Long‐term antibiotics for preventing recurrent urinary tract infection in children
- Probiotics for the prevention of paediatric antibiotic‐associated diarrhoea
- The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study
- Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Epanutin (phenytoin) 50mg Infatabs (Pfizer) supply issue
- Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study
- US FDA approves amifampridine for children with Lambert-Eaton myasthenic syndrome
- Health Secretary considers ‘all options’ to boost vaccine uptake
- Revised SPC: Bramitob (tobramycin) Nebuliser Solution
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Interventions for infantile seborrhoeic dermatitis (including cradle cap)
- Conference abstract – RCT reports cannabidiol (CBD) reduces convulsive seizure frequency in children and adolescents with Dravet syndrome
April 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
- Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer
- Liraglutide in Children and Adolescents with Type 2 Diabetes
- UNICEF reports over 20 million children worldwide missed out on measles vaccine annually in past 8 years creating a pathway to current global outbreaks
- BioMarin confirms all UK patients who took part in clinical trials of sapropterin dihydrochloride (Kuvan) for phenylketonuria (PKU) will be able to access drug after trials end
- Association of Exposure to Infections in Childhood With Risk of Eating Disorders in Adolescent Girls
- Revised SPCs: ORENCIA (abatacept) 50, 87.5 and 125mg solution for injection (pre-filled syringe)
- Revised SPC: Epistatus 10 mg Oromucosal Solution – Carer instructions for administration updated
- Brivaracetam add‐on therapy for drug‐resistant epilepsy
- Innovative child malaria vaccine to be tested in Malawi
- Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study
- Hepatitis C virus infection in children and adolescents
- Hepatitis B virus infection in children and adolescents
- UK immunisation schedule: the green book, chapter 11 (updated)
- Probiotics to prevent infantile colic
- Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
- Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial
- Rapid Over Infusion of Parenteral Nutrition (PN)- update to Patient Safety Alert NHS/PSA/W/2017/005 issued Sept 2017
- NHS staff and parents to gain access to crucial child health information
- Hepatitis virus infection in children and adolescents
- Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study
- Saving Babies’ Lives Version Two: A care bundle for reducing perinatal mortality
- Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
- Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial
- Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial
- Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
- Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation
- NIHR Signal: Does an antibacterial milk protein reduce infection in premature babies?
- Specialist neonatal respiratory care for babies born preterm (NG 124) – guidance
- New presentation: Fycompa (perampanel) 0.5 mg/ml oral suspension
- February BNF/BNFC eNewsletter
March 2019
- Transforming children’s services
- Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study
- Antibiotic treatment for newborns with congenital syphilis
- Current and Future Challenges for Children Across the World
- NHS England Specialised Commissioning document: Selective Dorsal Rhizotomy for treatment of spasticity in cerebral palsy
- Chloramphenicol: is it safe in breastfeeding?
- Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
- High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years
- NHS and Vertex remain deadlocked over price of Orkambi (lumacaftor/ivacaftor)
- Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA)
- Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial
- Association of Atopic Dermatitis With Sleep Quality in Children
- First 1000 days of life
- A priori choice of neuraxial labour analgesia and breastfeeding initiation success: a community-based cohort study in an Italian baby-friendly hospital
- What is the sodium content of medicines?
- First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
- Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
- Postoperative epidural analgesia versus systemic analgesia for thoraco‐lumbar spine surgery in children
- Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study
- Theophylline and aminophylline for prevention of acute kidney injury in neonates and children: a systematic review
- Biologics for paediatric severe asthma: trick or TREAT?
- School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review
February 2019
- Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
- Pertussis (whooping cough)
- Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial
- Universal antenatal screening for group B streptococcus may cause more harm than good
- Topiramate for juvenile myoclonic epilepsy
- Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial
- Spina bifida: information for parents
- Althea to launch cannabis based products in the UK
- Eisai submits application to extend licence of perampanel to include treatment of paediatric patients with epilepsy
- Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort
- Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis
- Child abuse and neglect- quality standard (QS179)
- Cases of measles in Europe at highest rate in a decade due to growing number of areas where parents are refusing vaccination for their children
- European Commission approves dasatinib in combination with chemotherapy for treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia
- Adoption of Peristeen at Alder Hey Children’s Hospital
- New product: OZALIN (midazolam) 2 mg/ml oral solution in single-dose container
- Education Secretary announces that up to 370 schools in England will take part in a series of trials testing different approaches to supporting young people’s mental health
- January 2019 BNF/ BNF C eNewsletter
- Childhood obesity: time for action report – government response
- European CHMP recommends license extension of abatacept (Orencia) for treatment of olyarticular juvenile idiopathic arthritis
- European CHMP recommends atazanavir (Atazanavir Krka) for treatment of HIV-1 in adults and children 6 years of age and older
- Mental health trial launches in schools in England
January 2019
- Limited evidence for non-drug treatment of childhood ADHD: DTB Select summary
- Seizures and quinolone antibiotics in children: a systematic review of adverse events
- Early access to medicines scheme (EAMS) scientific opinion: Dupilumab as a treatment of adolescent patients between 12 and 18 years of age with severe atopic dermatitis for whom the available systemic therapies are not suitable
- Depression in children and young people: identification and management – DRAFT guidance
- Children and young people exposed prenatally to alcohol
- Determining the reasons for poorly controlled asthma in an adolescent
- European Commission approves paediatric license extension of Orkambi (lumacaftor/ivacaftor) for cystic fibrosis
- Mental health services for children and young people
- PCV (13-valent, adsorbed): patient group direction (PGD) template
- Flutiform (fluticasone/ formoterol) approved in EU for treatment of children with asthma aged five years and over
- Tiotropium (Spiriva® Respimat®) for asthma in paediatric patients
- Sedation of children undergoing dental treatment
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults
- Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants
- Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial
- Childhood cancer burden: a review of global estimates
- Revised SPC: Ravicti (glycerol phenylbutyrate) 1.1 g/ml oral liquid
- Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above): Clinical Commissioning Policy
December 2018
- Paediatric extrapolation: A necessary paradigm shift
- Which medicines require extra care when switching between liquid and tablet/capsule formulations?
- BNF/BNFC eNewsletter December 2018
- Notification of the discontinuation of Zovirax (aciclovir) eye ointment 3% 4.5g
- Antibiotic and acid-suppression medications during early childhood are associated with obesity
- Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks
- Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study
- Ketogenic diets for drug‐resistant epilepsy
- Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist
- Timing of dornase alfa inhalation for cystic fibrosis
- Protocol‐directed sedation versus non‐protocol‐directed sedation in mechanically ventilated intensive care adults and children
- Melatonin in children with cancer
- Maternal immunisation to improve the health of HIV-exposed infants
- Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink
November 2018
- Ivacaftor approved in the EU to treat patients aged 12 to ≤24 months with certain mutations in the CFTR gene
- Early intervention for depression in young people: a blind spot in mental health care
- Manufacturers report positive outcomes for triple combination therapy in cystic fibrosis in preliminary data from phase III trials
- Children’s Commissioner for England publishes new analysis on the provision of children’s mental health services in England
- Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis
- Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children
- Help make medicines safer: report suspected side effects in children and during pregnancy
- European CHMP recommends approval of two paediatric formulations of lumacaftor / ivacaftor (Orkambi)
- AR101 Oral Immunotherapy for Peanut Allergy
- European CHMP endorses suspension or restrictions of quinolone and fluoroquinolone antibiotics due to disabling and potentially permanent adverse effects
- Childhood Immunisation CCG/GP Practice level coverage statistics 2017-18 (Management Information)
- European Medicines Agency issues guidance on safety monitoring of medicines used in children
- NIHR Signal: Oral steroids do not help hearing for children with glue ear
- Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
- Cannabis-based products for medicinal use: Guideline scope
- Heliox for croup in children
- Supporting public health: children, young people and families
- Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort
- Oral steroids for hearing loss associated with otitis media with effusion in children aged 2 8 years: the OSTRICH RCT
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
- New product: Symkevi (100mg tezacaftor/ 150mg ivacaftor) film coated tablets
- Cannabis based drugs: how will they be used in practice?
- European Commission approves Symveki (tezacaftor/ivacaftor) for treatment of selected patients with cystic fibrosis
- Chief medical officer (CMO) urges parents to get children vaccinated and ignore “social media fake news” about MMR vaccine
- Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review
- Cannabis-based products for medicinal use: Guidance to clinicians
- The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans ‘specials’
- Nebulised hypertonic saline for cystic fibrosis
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
October 2018
- Pregnancy problems: a guide for pharmacy
- US FDA approves sodium oxybate (Xyrem®) oral solution for treatment of cataplexy or excessive daytime sleepiness in paediatric narcolepsy patients
- GPhC statement on supplying valproate safely to women and girls
- Royal Pharmaceutical Society (RPS) practical guide to support pharmacist independent prescribers
- Maternal paracetamol intake and fetal ductus arteriosus constriction or closure: a case series analysis
- Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination
- Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
- October 2018 BNF/BNFC eNewsletter
- Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term
- European CHMP recommends approval of extension to existing indication of ivacaftor (Kalydeco)
- VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis
- Maternal Antibiotic Use During Pregnancy and Type 1 Diabetes in Children: A National Prospective Cohort Study
- Assessment and initial management of suspected behavioural insomnia in pre-adolescent children
- β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study
- Tuberculosis susceptibility and protection in children
- Strategies to improve detection and management of human parechovirus infection in young infants
- NHS England – Junior Epipen shortage
- Revised SPC: Isentress (raltegravir) 100 mg Granules for Oral Suspension – extension to neonates
- Specialist neonatal respiratory care for babies born preterm
- Needle size for vaccination procedures in children and adolescents
- Glucocorticoids for croup in children
- Improving children and young people’s mental health services
- Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children
- Improving children and young people’s mental health services
- Does melatonin improve sleep in children with neurodevelopmental disorders?
- Lipid‐based nutrient supplements for maternal, birth, and infant developmental outcomes
- Burosumab for treating X-linked hypophosphataemia in children and young people – guidance (HST8)
- Coeliac disease in children
- Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
September 2018
- Boosting the development of medicines for children
- Poor Metabolic Control in Children and Adolescents With Type 1 Diabetes and Psychiatric Comorbidity
- Positive Phase II data for once-weekly growth hormone analogue (somapacitan) in childhood growth hormone deficiency
- Meningitis report: Spotting a seriously ill child
- Ketorolac for postoperative pain in children
- September BNF/BNFC eNewsletter
- Medical and surgical interventions for the treatment of urinary stones in children
- Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial
- Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Long-term developmental effects of withholding parenteral nutrition for 1 week in the paediatric intensive care unit: a 2-year follow-up of the PEPaNIC international, randomised, controlled trial
- Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
- Impact of antibiotics for children presenting to general practice with cough on adverse outcomes: secondary analysis from a multicentre prospective cohort study
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
- Bronchiectasis in children: diagnosis and treatment
- Tisagenlecleucel to be made available on NHS for children and adults up to age 25 years for B cell acute lymphoblastic leukaemia
- Burosumab for treating X-linked hypophosphataemia in children and young people – Final appraisal determination
- The Good Childhood Report 2018
- Treatment of extravasation injuries in infants and young children: a scoping review and survey
- An overview of the EU’s orphan designation programme
- Face‐to‐face interventions for informing or educating parents about early childhood vaccination
- Clonazepam add‐on therapy for refractory epilepsy in adults and children
- Revised SPC: Blincyto (blinatumomab) solution
August 2018
- Mepolizumab approved in EU for treatment of paediatric patients with severe eosinophilic asthma
- Paracetamol (acetaminophen) for patent ductus arteriosus (a blood vessel necessary for fetal survival) in preterm and low birth weight infants
- Interventions for infantile haemangiomas of the skin
- Honey for acute cough in children
- BNF and BNF for Children Update: August 2018
- Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children
- National Paediatric Diabetes Audit
- Perinatal Marijuana Use and the Developing Child
- Paediatric intensive care and neonatal intensive care airway management in the United Kingdom: the PIC‐NIC survey
- Video on valproate use during pregnancy to support healthcare professionals
- The Risk of Offspring Psychiatric Disorders in the Setting of Maternal Obesity and Diabetes
- Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association
- Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study
- Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth
- FDA approve lumacaftor/ivacaftor (Orkambi) Cystic Fibrosis for Children Ages 2-5 Years in US
- Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study
- Effect of a Responsive Parenting Educational Intervention on Childhood Weight Outcomes at 3 Years of Age: The INSIGHT Randomized Clinical Trial
- NIHR Signal Adding emollients to the bath unlikely to help children with eczema
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
- Revised SPC: Rotarix (Human rotavirus, RIX4414 strain, live, attenuated) Oral Applicator
- Revised SPC: Briviact (brivaracetam) 10 mg/ml oral solution – licensed from 4 years of age
- Safety and Side Effects of Rifampin versus Isoniazid in Children
July 2018
- Association Between the New York Sepsis Care Mandate and In-Hospital Mortality for Pediatric Sepsis
- BNF and BNFC Update: July 2018
- Revised SPC: Gentamicin Intrathecal 5mg/ml – no longer contra-indicated in under one year of age
- Clarification of the doses at extremes of body-weight statement for vancomycin in BNF and BNF for Children
- Antidepressant prescriptions for children on the rise
- In use product safety assessment report for intravenous paracetamol in paediatrics
- Scientific Advisory Committee on Nutrition (SACN) publishes report on ‘Feeding in the first year of life’
- Perinatal Marijuana Use and the Developing Child
- Recurrent lower respiratory tract infections in children
- Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden
June 2018
- NIHR Signal: Oral ibuprofen may be an option for closing patent ductus arteriosus in premature babies
- Xenidate XL (methylphenidate) Prolonged-release Tablets: Checklist before prescribing
- MHRA will continue to monitor safety of opioid patches after baby’s death
- European CHMP recommends approval of tisagenlecleucel (Kymriah) for acute lymphoblastic leukaemia (ALL) and diffuse large B cell lymphoma (DLBCL)
- Revised SPC: Curosurf (poractant alfa)
- Public Health England and Disney UK launch Change4Life Train Like A Jedi programme
- June BNF/BNFC eNewsletter
- Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
- Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
- Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study
- UK to review medical cannabis policy
- Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies
- The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
- Idiopathic nephrotic syndrome in children
- Burosumab for treating X-linked hypophosphataemia in children and young people: Evaluation consultation
- Spiriva (tiotropium) Respimat licensed in UK for treatment of asthma in patients aged six years and above
- Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial
- Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
- At-risk children with asthma (ARC): a systematic review
- European CHMP recommends approval of adalimumab biosimilars (Halimatoz, Hefiya and Hyrimoz)
- European CHMP recommends approval of nitisinone (Nityr) for treatment of hereditary tyrosinemia type 1
May 2018
- Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review
- Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality – A Systematic Review and Meta-analysis
- Mass chemoprophylaxis for control of outbreaks of meningococcal disease
- Adolescent affective symptoms and mortality
- Higher versus lower amino acid intake in parenteral nutrition for newborn infants
- Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants
- Important considerations for interpreting biochemical tests in children
- US FDA accepts supplemental biologics license application for prophylactic and paediatric use of Coagadex® (Coagulation Factor X, Human) for treatment of hereditary factor X deficiency
- Antibiotics at the time of removal of central venous catheter to reduce morbidity and mortality in newborn infants
- Immunoglobulin for alloimmune hemolytic disease in neonates
- European Medicines Agency investigating new study suggesting increased risk of neural tube defects in infants born to women who took dolutegravir at conception
- Systemic corticosteroids for acute otitis media in children
- Developmental follow-up of children and young people born preterm – quality standard (QS169)
- Cystic fibrosis – quality standard (QS168)
- Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease
- The use of complementary and alternative medicines during breastfeeding: results from the Herbal supplements in Breastfeeding InvesTigation (HaBIT)
- US FDA approves oral brivaracetam for the treatment of partial-onset (focal) seizures in paediatric patients
- Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates
- FDA expands approval of fingolimod (Gilenya) to treat multiple sclerosis in paediatric patients
- Which weak opioids can be used during breastfeeding? Considering the evidence for codeine, dihydrocodeine, and tramadol
- Prevalence estimates and risk factors for early childhood wheeze across Europe: the EuroPrevall birth cohort
- Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
- Which oral antihistamines are safe to use whilst breastfeeding?
- Vaccines for preventing influenza in healthy children
- Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis
- NIHR Signal: Domperidone increases breast milk production in mothers of premature babies
- Can mothers breastfeed after a medical termination of pregnancy?
- Breastfeeding and lithium: is breast always best?
- Inhaled mannitol for cystic fibrosis
- Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness
- Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?
- Effect of Atropine With Propofol vs Atropine With Atracurium and Sufentanil on Oxygen Desaturation in Neonates Requiring Nonemergency Intubation: A Randomized Clinical Trial
- Extended-release methylphenidate – An updated review of the pharmacokinetic profiles of available preparations
- Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions
April 2018
- European CHMP recommends approval of new paediatric indication for dasatinib (Sprycel)
- Maternal caffeine intake during pregnancy and childhood growth and overweight: results from a large Norwegian prospective observational cohort study
- Oral antiplatelet agents – are they safe in breastfeeding?
- Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
- April 2018 BNF/BNF-C eNewsletter.
- Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children
- RMOC Recommendation: Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines
- Ministers write letter over Orkambi (lumacaftor/ivacaftor) access
- Cardiopulmonary Resuscitation in Infants and Children With Cardiac Disease: A Scientific Statement From the American Heart Association
- Weighing the risks of valproate in women who could become pregnant
- Large differences in neonatal drug use between NICUs are common practice: time for consensus?
- NIHR Signal: Lorazepam confirmed as first-line treatment for stopping prolonged seizures in children
- Gabapentin and pregabalin—are they safe whilst breastfeeding?
- Which medicines require extra care when switching between liquid and tablet/capsule formulations?
- Medical and dietary interventions for preventing recurrent urinary stones in children
- Public Health England continues to urge parents to look out for the symptoms of scarlet fever following significant upsurge in cases
- Early erythropoiesis-stimulating agents in preterm or low birth weight infants
- Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies
- Altemia receives orphan drug designation from the European Medicines Agency for paediatric sickle cell disease
- Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment
- The routine immunisation schedule from Spring 2018
- Supplemental New Drug Application for paediatric use of perampanel submitted to US FDA
March 2018
- Be brave –
- March BNF/BNFC eNewsletter
- NIHR Signal: Self-care support for children with long-term conditions may reduce emergency costs
- European CHMP recommends extension of fosaprepitant indication to include paediatric patients
- Nilotinib (Tasigna®) approved in the US for treatment of paediatric patients with Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase
- The Relationship Between Oseltamivir and Suicide in Pediatric Patients
- Methylphenidate for children and adolescents with autism spectrum disorder
- Causes of death among children aged 5–14 years in the WHO European Region: a systematic analysis for the Global Burden of Disease Study 2016
- British Society of Haematology Guideline: management of thrombotic and haemostatic issues in paediatric malignancy
- Enzyme replacement therapy for infantile-onset Pompe disease
- Risk Minimisation Material for use of tenofovir disoproxil in adults and adolescent children with chronic hepatitis B
- Attention deficit hyperactivity disorder – quality standard (QS39)
- Effect of a Pediatric Early Warning System on All-Cause Mortality in Hospitalized Pediatric Patients: The EPOCH Randomized Clinical Trial
- Chloral hydrate as a sedating agent for neurodiagnostic procedures in children
- Attention deficit hyperactivity disorder: diagnosis and management – updated guidance (NG87)
- The Changing Landscape of Pediatric Migraine Therapy: A Review
- Are we listening? A review of children and young people’s mental health services
- Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non–Vaccine-Targeted Infections From 24 Through 47 Months of Age
- Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations
- Should universal distribution of high dose vitamin A to children cease?
- ‘Pill School’ project launched to teach children how to swallow tablets
- Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study
- Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations
- Children’s toothache is becoming everybody’s business: where do parents go when their children have oral pain in London, England? A cross-sectional analysis
- Diet during pregnancy and infancy and risk of allergic or autoimmune disease: A systematic review and meta-analysis
February 2018
- FDA accepts New Drug Application for Stannsoporfin for severe neonatal jaundice
- February BNF/BNFC eNewsletter
- European CHMP recommends approval of glibenclamide (Amglidia) for the treatment of neonatal diabetes mellitus in newborns, infants and children
- Accuracy of intravenous and enteral preparations involving small volumes for paediatric use: a review
- Infant Hospitalizations and Mortality After Maternal Vaccination
- Discontinuities and disruptions in drug dosage guidelines for the paediatric population
- The social and economic impact of ADHD
- Maternal thyroid function and child educational attainment: prospective cohort study
- Implementing an oxygen weaning guideline for babies with chronic neonatal lung disease
- Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children
- Oseltamivir or zanamivir – can mothers breastfeed after treatment for influenza?
- Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
- Intravenous immunoglobulin for the treatment of childhood encephalitis
- Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
- Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm
- Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
- Prenatal exposure to acetaminophen and children’s language development at 30 months
- Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease
- NIHR Signal: Takeaways linked to increased cardiovascular risk factors and obesity in children
- Influenza vaccines for preventing acute otitis media in infants and children
- Reducing inappropriate antibiotic prescribing for children in primary care: a cluster randomised controlled trial of two interventions
- Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
- Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
- Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma
- Effectiveness of a childhood obesity prevention programme delivered through schools, targeting 6 and 7 year olds: cluster randomised controlled trial (WAVES study)
- Vitamin A supplements for reducing mother‐to‐child HIV transmission
- Junior doctors’ communication with hospital pharmacists about prescribing: findings from a qualitative interview study
- Is the provision of paediatric oral liquid unlicensed medicines safe?
- Growth hormone therapy for people with thalassaemia
- Public Health England urges vigilance about spotting signs of scarlet fever
- High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants
- Treatments for priapism in boys and men with sickle cell disease
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
January 2018
- Experts urge addition of folic acid to flour to halt “avoidable tragedy” of birth defects
- Transition from Child and Adolescent Mental Health Services to Adult Mental Health Services
- Vitamin K supplementation for cystic fibrosis
- Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
- Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
- Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
- Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
- Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial Antiepileptic drugs for chronic non‐cancer pain in children and adolescents
- Antidepressants for chronic non‐cancer pain in children and adolescents
- Slow advancement of enteral feed volumes to prevent necrotising enterocolitis in very low birth weight infants
- Interventions for preventing and managing advanced liver disease in cystic fibrosis
- Patient information leaflet – Group B Strep (GBS) in pregnancy and newborn babies
- State of Child Health: One Year On
- European Commission approves ipilimumab for the treatment of paediatric patients 12 years and older with unresectable or metastatic melanoma
- Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus
- Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis
- Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease
- Sildenafil for pulmonary hypertension in neonates
- Paracetamol (acetaminophen) for chronic non‐cancer pain in children and adolescents
- Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents
- Fluid supplementation for neonatal unconjugated hyperbilirubinaemia
- US FDA accepts for review application for clobazam oral Soluble Film (OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and above
- European Medicines Agency publishes additional reports on decision-making for orphan medicines
- The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data
- GPs’ experiences of diagnosing and managing childhood eczema: a qualitative study in primary care
- Safety and efficacy of tiotropium in children aged 1–5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial
- MHRA advises parents and carers to inspect Buccolam oral syringes before use following the EMA safety alert
- Networked approach to implementing NG61 (End of life care for infants, children & young people)
- Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial
- Antibiotic prescribing quality for children in primary care: an observational study
- Defect with Buccolam (midazolam) oral syringes
- FDA approves paediatric license extension of Fluarix quadrivalent (influenza vaccine) for babies 6 months and older
- Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services
- Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis
- Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
- Nasogastric (NG) feeding tubes – recall due to risk of neonatal or paediatric patient choking on ENFIT connector cap
- Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring
- Marketing Authorisation Application submitted in EU for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome
- Admissions of inequality: emergency hospital use for children and young people
- Improving treatment of asthma attacks in children
- Sickle cell treatment endari receives positive opinion on paediatric investigation plan from European Medicines Agency
- Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero
December 2017
- December BNF/BNF-C eNewsletter
- Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections
- Nasogastric (NG) feeding tubes – recall due to risk of neonatal or paediatric patient choking on ENFIT connector cap
- Fingolimod granted FDA breakthrough therapy designation for paediatric multiple sclerosis (MS)
- Statins for children with familial hypercholesterolemia
- European CHMP recommends approval of paediatric license extension of emtricitabine / tenofovir disoproxil (Truvada)
- Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A Scientific Statement From the American Heart Association
- Opioids for cancer‐related pain in children and adolescents
- Mycophenolate: updated recommendations for contraception for men and women
- Developmental follow-up of children and young people born preterm: Quality standard consultation
- Cystic fibrosis: Quality standard consultation
- Oral dextrose gel to prevent hypoglycaemia in at‐risk neonates
- Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents
- Medical Cannabinoids in Children and Adolescents: A Systematic Review
- Opioids for chronic non‐cancer pain in children and adolescents
- Eating disorders in children and young people
- Management for intussusception in children
- Transforming children and young people’s mental health provision: a green paper
- Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
- Revised SPC: Cubicin (daptomycin) injection – paediatric extension
- Diagnostic Accuracy of Pediatric Teledermatology Using Parent-Submitted Photographs: A Randomized Clinical Trial
- Antibiotics for neonates born through meconium‐stained amniotic fluid
- Children and young people’s survey 2016
- Asthma: diagnosis, monitoring and chronic asthma management – guidance (NG80)
November 2017
- European Commission approves license extension for nilotinib to include first and second-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) in children
- Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
- Undernutrition and severe acute malnutrition in children
- Cyanotic congenital heart disease following fertility treatments in the United States from 2011 to 2014
- Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
- National Maternity and Perinatal Audit: Clinical report 2017
- European CHMP issues positive opinion for paediatric license extension of Nplate (romiplostim) for chronic immune (idiopathic) thrombocytopenic purpura
- European CHMP issues positive opinion for paediatric license extension of Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide fumarate) for treatment of HIV
- Revised SPC: Emend (aprepitant) 125 mg powder for oral suspension
- Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
- Increasing admissions to paediatric intensive care units in England and Wales: more than just rising a birth rate
- Atrial Fibrillation Burden in Young Patients with Congenital Heart Disease
- Interim guidelines for the public health management of scarlet fever outbreaks in schools, nurseries and other childcare settings October 2017
October 2017
- European approval for license extension for icatibant for the symptomatic treatment of acute attacks of hereditary angioedema in patients with C1-esterase-inhibitor deficiency
- CQC completes initial review of mental health services for children and young people
- Diagnosis and management of cystic fibrosis: summary of NICE guidance
- Strimvelis for treating severe combined immunodeficiency caused by adenosine deaminase deficiency: Appraisal Consultation Document
- Interventions to prevent global childhood overweight and obesity: a systematic review
- DTaP/IPV (Infanrix®-IPV or Repevax®): patient group direction (PGD) template
- Management of paediatric hernia
- Short and long term complications of in utero exposure to lamotrigine
- CHMP adopts positive opinion for licence extension for paeds aged > 3years for peg-interferon alpha-2a
- CHMP adopts positive opinion for licence extension in paeds 1-17 years for daptomycin
- Live attenuated influenza vaccine for children
- Effect of iodine supplementation in pregnant women on child neurodevelopment: a randomised, double-blind, placebo-controlled trial
- Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
- Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes
- Revised SPC: Vimpat (Lacosamide) preparations – use in children from 4 years of age
- Ivacaftor (Kalydeco®)
- Immunosuppressive therapy for kidney transplant in children and young people – guidance (TA482)
- Cerebral palsy in children and young people
- ADHD in children and young people: prevalence, care pathways, and service provision
- European Medicines Agency (EMA) issues updated annex to excipient guidelines providing new safety advice for 15 excipients
- Dose correction of Ironorm (ferrous sulphate) drops in BNF for Children
- Child abuse and neglect – guidance (NG76)
- European Medicines Agency (EMA) publishes summary of its public hearing on valproate in pregnancy
- Appendix 1 Interactions: new interactions content for the BNF and BNF for Children has now been launched
- All schools can now purchase emergency adrenaline auto-injectors without prescription
- Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study
- Sepsis in children: advice for health visitors and school nurses
- Conference report: Infants prescribed antacids for reflux have increased risk of bone fractures
September 2017
- September BNF/BNFC eNewsletter
- Faltering growth- recognition and management of faltering growth in children – guidance (NG75)
- Urinary tract infection in under 16s: diagnosis and management – guidance (CG54): update
- Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children
- Updated Risk Minimisation Materials for Cinryze®▼ use in paediatric patients (C1 esterase inhibitor [human])
- EU approval for paediatric use of lacosamide (Vimpat)
- New product: Cystadrops (mercaptamine) 3.8mg/ml eye drops
- Renal toxicity and chemotherapy in children with cancer
- Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014
- Childhood Vaccination Coverage Statistics, England, 2016-17
- Access and waiting times in children and young people’s mental health services
- Health protection in schools and other childcare facilities
- Revised SPC: Varilrix (live attenuated varicella-zoster virus – Oka strain) vaccine
- Using emergency adrenaline auto-injectors in schools – guidance for schools
- Single-injection vaccine device still a long way off
- National Institute for Health Research Highlight: Childhood Eczema
- European CHMP recommends paediatric license extension of Stribild (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil)
- European CHMP recommends paediatric license extension of nilotinib (Tasigna)
- European CHMP recommends paediatric license extension of icatibant (Firazyr)
- End of life care for infants, children and young people (QS160)
- European Medicines Agency approves license extension for Humira (adalimumab) for anterior uveitis to include children
- FDA acknowledges qualified health claim linking early peanut introduction and reduced risk of developing peanut allergy
- Lancet Series on paediatric surgery
- Joint Scientific Advisory Committee on Nutrition (SACN)/ Committee on Toxicity (COT) Working Group statement on the timing of introduction of allergenic foods into the infant diet
- Flu immunisation for early years settings including child minders
- INN-108 (mesalamine and 4-aminophenylacetic acid [4-APAA]) granted Orphan Drug designation in the US for paediatric ulcerative colitis
- The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
- Revised SPC: Decapeptyl SR 22.5mg (triptorelin pamoate) – new indication for central precocious puberty
- Supporting junior doctors in safe prescribing
- Tracleer (bosentan) 32mg tablet for oral suspension approved in US for treatment of paediatric patients with pulmonary arterial hypertension
- London asthma standards for children and young people: Driving consistency in outcomes for children and young people across the capital
- Attention deficit hyperactivity disorder: 1 diagnosis and management update draft for consultation
- Guanfacine for the treatment of attention deficit hyperactivity disorder (ADHD)
- European Commission approves paediatric license extension and paediatric formulation of cinacalcet (Mimpara)
- New Drug Application for dasotraline for attention deficit hyperactivity disorder (ADHD) submitted to the US FDA
- Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis
August 2017
- FDA approves benznidazole for paediatric Chagas disease
- Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies
- Type 2 diabetes in adolescents and young adults
- Biologics License Application seeking approval of burosumab for the treatment of X-Linked Hypophosphatemia submitted to the FDA
- Asthma action plans for healthcare professionals working with non-English speakers
- Association of Childhood Body Mass Index and Change in Body Mass Index With First Adult Ischemic Stroke
- The Royal College of GPs and the Royal College of Paediatrics and Child Health commit to five shared principles
- US FDA to re-evaluate prescription opioid medications to treat cough in children
- Government announces next stage of childhood obesity plan
- Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review
- Adrenaline auto-injectors: updated advice after European review
- Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis
- Acute Respiratory Distress Syndrome
- Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height
- Hypersalivation – can hyoscine hydrobromide be used to treat it?
- Hypersalivation – can glycopyrronium be used to treat it?
- Fever in under 5s: assessment and initial management (CG160) – update
- Developmental follow-up of children and young people born preterm – guidance (NG72)
- US FDA grants “Orphan Drug” designation for PLX-200 for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)
- The National Childhood Flu Immunisation Programme 2017/18: Information for healthcare practitioners
- Association between maternal vitamin D status in pregnancy and neurodevelopmental outcomes in childhood: results from the Avon Longitudinal Study of Parents and Children (ALSPAC)
- Does inhaled steroid therapy help emerging asthma in early childhood?
- Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study
- Royal College of Paediatrics and Child Health: Position Statement on breastfeeding in the UK
- NIHR Signal: Fluoride varnish every six months helps protect children’s permanent teeth from decay
- NIHR Signal: Prescribing regular drugs to prevent febrile convulsions risks more harm than benefit
- Asfotase alfa for treating paediatric-onset hypophosphatasia – guidance (HST6)
- European Commission approves license extension for ledipasvir/sofosbuvir (Harvoni) to include adolescents
- Epilim (sodium valproate) risk management materials: Letters to healthcare professionals, and poster warning of use of valproate products in girls/women
July 2017
- Improving the global diagnosis and management of asthma in children
- Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis
- Inpatient provision for children and young people with mental health problems
- Strensiq (asfotase alfa) risk management materials: Self-injection guide and guide for parents/carers administering to infants
- Advances in the diagnosis of pneumonia in children
- FDA approves licence extension for ipilimumab to include children 12 years and older with unresectable or metastatic melanoma (MM)
- Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine paediatric intensive care
- The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity
- European Medicines Agency approves ciclosporin eye drops (Verkazia) for vernal keratoconjunctivitis (VKC) in children from four years of age and adolescents
- European Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for extension of license for sofosbuvir (Sovaldi) to include paediatric population
- European Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for extension of license for lacosamide (Vimpat) to include paediatric population
- European Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for extension of license for adalimumab (Humira) for uveitis
- Revised SPC: Infanrix hexa (Diphtheria/tetanus/pertussis/hepatitis B/poliomyelitis/Haemophilus influenzae type b), Powder and suspension for suspension for injection
- Number of children getting enough physical activity drops by 40%
- A telephone survey to determine the experiences of children and their parents/carers, following the initiation of a new medicine
- National Paediatric Diabetes Audit: Hospital Admissions and complications
- Stimulant medication to treat attention-deficit/hyperactivity disorder
- Blinatumomab (Blincyto) receives full approval in US as treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
- Orphan drug application for INN-108 submitted to FDA for treatment of ulcerative colitis in children
- Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people – guidance (TA455)
- Clonidine for sedation and analgesia for neonates receiving mechanical ventilation
- Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
- Immunisations for young people
- Childhood immunisation: quick guide for parents of premature babies (update)
- Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children’s Oncology Group
- Immunisations at one year of age (for babies born on or after the 1 August 2017)
- Quarterly vaccination coverage statistics for children aged up to five years in the UK (COVER programme): January to March 2017
- Enuresis: practical guidelines for primary care
- Updated Educational Risk Minimisation Materials for Benepali® (etanercept biosimilar)
- Barriers to and facilitators of smoking cessation in pregnancy and following childbirth: literature review and qualitative study
- June BNF/BNFC eNewsletter
June 2017
- Withdrawal of the marketing authorisation application for levamisole (Elmisol) for paediatric nephrotic syndrome
- Paediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
- State of child health: The report in a glance
- Each Baby counts: 2015 Summary report
- Urinary tract infection in under 16s: DRAFT guideline update
- Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update
- Flu vaccines for children
- Child and maternal health data and intelligence: a guide for health professionals
- Study results demonstrate minimal to no placental transfer of certolizumab (Cimzia®) from mother to infant during third trimester
- Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial
- Burtomab receives US Breakthrough Therapy Designation for treatment of paediatric patients with relapsed or refractory metastatic neuroblastoma
- New product: Epistatus (midazolam) 10 mg Oromucosal Solution
- Identifying and managing neonatal hypoglycaemia in full term infants
- BSACI guideline for the diagnosis and management of peanut and tree nut allergy
- Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial
- Measles, mumps and rubella (MMR) vaccine information leaflet for new mums
- Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
- Diagnosis and management of inflammatory bowel disease in children
May 2017
- Vaccine update: issue 263, May 2017
- Arginine supplementation for prevention of necrotising enterocolitis in preterm infants
- Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy
- Levetiracetam containing products 100 mg/mL oral solution presentations: Risk of medication errors associated with overdose
- European Committee for Orphan Medicinal Products (COMP) grants positive opinion for ibutamoren for the treatment of paediatric growth hormone deficiency
- Very strict blood sugar control in critically ill children provides no benefit
- Asthma education for school staff
- Stroke in Childhood: Clinical guideline for diagnosis, management and rehabilitation (2017)
- Cardiopulmonary Resuscitation in Adults and Children With Mechanical Circulatory Support: A Scientific Statement From the American Heart Association
- Enuresis: practical guidelines for primary care
- U.S. FDA accepts for review supplemental new drug application (sNDA) for eslicarbazepine acetate for partial-onset seizures in children aged 4 To 17 years
- Conference report: Study evaluating lurasidone in children and adolescents with bipolar depression meets primary endpoint
- Questions and answers on dexrazoxane (Cardioxane)
- European CHMP recommends paediatric license extension of travaprost (Izba) for ocular hypertension or paediatric glaucoma
- Identification and Management of Neonatal Hypoglycaemia in the Full Term Infant – A Framework for Practice
- Conference report: Early Antacid Exposure Increases Fracture Risk in Young Children
- May BNF/BNFC eNewsletter
- Topiramate monotherapy for juvenile myoclonic epilepsy
- NICE consults on draft quality standard on cerebral palsy in children
- Infant Feeding and Risk of Type 1 Diabetes in Two Large Scandinavian Birth Cohorts
- A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU
- Epinephrine Concentrations in EpiPens After the Expiration Date
- Ongoing vomiting in an infant
- Draft clinical guideline on diagnosis and management of cystic fibrosis issued for consultation
- Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
- Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease
- Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update .
- Pharmacological interventions for recurrent abdominal pain in childhood